Skip to main content

Table 1 MIC and MBC of P128 against 32 Staphylococcus aureus strains

From: Antistaphylococcal activity of bacteriophage derived chimeric protein P128

Sl. No. Strain MIC (μg/mL) MBC (μg/mL)
1 BK#13725 2 2
2 BK#9894 2 4
3 BK#2926 (USA100) 2 8
4 BK#13993 4 4
5 BK#14035 4 16
6 BK#12003 4 16
7 BK#13385 4 32
8 BK#15273 4 4
9 BK#14942 4 4
10 BK#19069 (USA300) 4 8
11 BK#11147 4 4
12 BK#15271 4 4
13 BK#14483 4 > 32
14 BK# 13387 4 8
15 BK#13228 8 8
16 BK#14935 8 16
17 BK# 13237 8 32
18 BK#14655 8 8
19 BK#18552 8 16
20 BK#9897 C (USA400) 8 8
21 BK#14284 16 16
22 BK#13180 16 16
23 BK#8374 (COL) 16 64
24 BK#11512 16 16
25 BK#11433 16 16
26 BK#13641 16 64
27 BK#2394 32 64
28 BK#9918 1 1
29 BK#14780 8 8
30 BK#15383 16 16
31 USA500/1 16 ND
32 USA500/2 64 ND
33 S. carnosus, ATCC 51365 0.5 0.5
34 S. aureus, ATCC 25923 4 4
  1. MIC was determined using a modification of the CLSI broth microdilution method. P128 was tested at 256 to 0.125 μg/mL. S. aureus ATCC 25923 and S. carnosus ATCC 51365 were used as control strains. MBC was determined following the CLSI procedure by plating 100 μL from the MIC, MIC × 2, MIC × 4, and MIC × 8 wells on LB agar, and incubating the plates overnight at 37°C. Strains 1-30 constitute a global panel of distinct clinical isolates (MRSA, strains1-27; MSSA, strains 28-30) obtained from the Public Health Research Institute (NJ, USA); strains 31 and 32 are USA500.